Catalog No. |
TD-VK515016 |
Description |
Diridavumab, the alternative name, CR6261, is a human monoclonal antibody directed against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a Dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants). |
Species reactivity |
Influenza A virus |
Applications |
Research Grade Biosimilar |
Host species |
Human |
Isotype |
IgG1, lambda |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
HA/Hemagglutinin |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
P03455 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
CR-6261,CR6261,CAS:1393659-46-5 |
Background |
Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus. |
Note |
For research use only. Not for use in clinical or therapeutic applications. |